Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform's ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets.
The platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model. This demonstration marks a significant step for the company as it seeks to commercialize its AI technology beyond internal drug development.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
withZeta.ai, Lantern's multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. The platform's ability to integrate diverse data types could significantly reduce the time and cost associated with early-stage drug discovery, potentially enabling faster development of therapies for underserved patient populations.
The live demo is expected to attract attention from pharmaceutical companies, biotech firms, and academic researchers interested in leveraging AI for oncology research. By offering a subscription model, Lantern aims to make advanced AI capabilities accessible to a broader range of organizations, potentially accelerating innovation across the industry. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
For more details on the demonstration and the company's latest updates, visit the company's newsroom at https://ibn.fm/LTRN. The full press release is available at https://ibn.fm/wzevl.
